Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2016 May 26:22:1773-81.
doi: 10.12659/msm.895548.

Improvement of Survival Rate for Patients with Hepatocellular Carcinoma Using Transarterial Chemoembolization in Combination with Three-Dimensional Conformal Radiation Therapy: A Meta-Analysis

Houqiao Bai  1 , Peng Gao  1 , Hao Gao  2 , Guangxi Sun  1 , Chonghai Dong  1 , Jian Han  3 , Guosheng Jiang  4
Affiliations
Meta-Analysis

Improvement of Survival Rate for Patients with Hepatocellular Carcinoma Using Transarterial Chemoembolization in Combination with Three-Dimensional Conformal Radiation Therapy: A Meta-Analysis

Houqiao Bai et al. Med Sci Monit. .

Abstract

BACKGROUND Transarterial chemoembolization (TACE) has been used alone or in combination with three-dimensional conformal radiation therapy (3DCRT) for treating hepatocellular carcinoma (HCC). The overall survival rate of HCC patients undergoing both treatments, however, has not been systematically studied. The aim of this meta-analysis-based study was to evaluate the overall efficacy of the combined therapy or monotherapy, thereby providing information for clinical treatment. MATERIAL AND METHODS We searched Google Scholar, PubMed, and Chinese National Knowledge Infrastructure (CNKI) for eligible studies, and a total of 17 case-control studies (including HCC patients treated by TACE plus 3DCRT or TACE alone) were included to perform the meta-analysis. Based on the available data, we assessed the improvements of 1-year, 2-year, and 3-year survival rate for the combination therapy of TACE and 3DCRT or TACE alone. Furthermore, the analysis was also stratified by the tumor response: complete response (CR), partial response (PR), no response (NR) and progressive disease (PD). Statistical analysis was performed using STATA 12 (Stata Statistical Software: Release 12). RESULTS The results show that HCC patients receiving combination therapy have significantly increased overall survival rate when compared to those receiving TACE alone (1-year survival rate: OR=1.95, 95% CI 1.54-2.47, p=7.3×10^-8; 2-year survival rate: OR=1.87, 95% CI 1.49-2.34, p=1.6×10^-7; 3-year survival rate: OR=2.00, 95% CI 1.52-2.64, p=1.8×10^-6). CONCLUSIONS Assessment of tumor response demonstrates that the combination therapy can efficiently increase the tumor response rate (CR+PR: OR=2.29, 95% CI 1.70-3.08, p=1.1×10^-7), with a lower rate of subsequent tumor development (PD: OR=0.25, 95% CI 0.15-0.40, p=5.5×10^-8).

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flow diagram of eligible studies included in the meta-analysis.
Figure 2
Figure 2
Forest plot of meta-analysis for the comparison of the combined therapy with TACE alone in terms of overall survival rates. (A) Meta-analysis of 1-year survival. (B) Meta-analysis of 2-year survival. (C) Meta-analysis of 3-year survival.
Figure 3
Figure 3
Forest plot of meta-analysis for the comparison of the combined therapy with TACE alone on tumor response. (A) Meta-analysis of CR+PR. (B) Meta-analysis of CR. (C) Meta-analysis of PR. (D) Meta-analysis of PD.
Figure 4
Figure 4
Begg’s funnel plot of meta-analysis for the comparison of the combined therapy with TACE alone in terms of overall survival rates. (A) One-year survival. (B) Two-year survival. (C) Three-year survival.
Figure 5
Figure 5
Begg’s funnel plot of meta-analysis for the comparison of the combined therapy with TACE alone on tumor response. (A) CR+PR. (B) CR. (C) PR. (D) PD.
See this image and copyright information in PMC

References

    1. Xu H, He Y-T, Zhu J-Q. Liver cancer mortality trends during the last 30 years in Hebei province: Comparison results from provincial death surveys conducted in the 1970’s, 1980’s, 1990’s and 2004–2005. Asian Pac J Cancer Prev. 2012;13(5):1895–99. - PubMed
    1. Heinzow HS, Brockmann JG, Köhler M, et al. Liver transplantation versus supraselective transarterial chemoembolization in palliative patients with hepatocellular carcinoma exceeding the Milan Criteria – is it time for a more individual approach? Ann Transplant. 2013;18:515–24. - PubMed
    1. Roayaie S, Jibara G, Tabrizian P, et al. The role of hepatic resection in the treatment of hepatocellular cancer. Hepatology. 2015;62(2):440–51. - PubMed
    1. Murata S, Mine T, Sugihara F, et al. Interventional treatment for unresectable hepatocellular carcinoma. World J Gastroenterol. 2014;20(37):13453–65. - PMC - PubMed
    1. Cheng YC, Chen TW, Fan HL, et al. Transarterial chemoembolization for intrahepatic multiple recurrent HCC after liver resection or transplantation. Ann Transplant. 2014;19:309–16. - PubMed

Publication types

MeSH terms